Table 1.

New Drugs in the Pipeline in the Field of SLE

Drug	Trial	Target	References
CNTY-101	Phase I approved by the FDA	CNTY-101 uses iPSC-derived natural killer cells with CD19-directed CAR, targeting CD8 + T cells, CD4 + T cells and NK cells	https://investors.centurytx.com/node/8076/pdf
Deucravacitinib	Phase II completed	Deucravacitinib inhibits tyrosine kinase 2 inhibitor binding to the pseudo kinase domain	Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2023;75(2):242–252. https://doi.org/10.1002/art.42391
Orelabrutinib	Phase Ib /IIa completed	Covalent inhibitor of Bruton’s tyrosine kinase	Mok CC. Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline. Drugs. 2023;83(6):479–496.https://doi.org/10.1007/s40265-023-01856-x
Saphnelo	Phase III completed	Type I receptor antagonists	Tanaka Y. Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice [published correction appears in RMD Open. 2024 Apr 4;10(2):]. RMD Open. 2023;9(3):e003270. https://doi.org/10.1136/rmdopen-2023-003270
JNJ-55920839	Phase I completed	Neutralizes IFNα subtypes and IFNω	Jordan J, Benson J, Chatham WW, et al. First-in-Human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomized placebo-controlled phase 1 trial. Lancet Rheumatol. 2020;2(10):e613-e622. https://doi.org/10.1016/S2665-9913(20)30223-X
Atacicept	Phase II completed	Binds to BAFF and APRIL	Wallace DJ, Isenberg DA, Morand EF, et al. Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(11):5379–5389. https://doi.org/10.1093/rheumatology/keab115